Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
about
Aminoglycoside Prescribing and Surveillance in Cystic FibrosisVaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisIntravenous antibiotics for pulmonary exacerbations in people with cystic fibrosisIntravenous antibiotics for pulmonary exacerbations in people with cystic fibrosisVaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisDuration of intravenous antibiotic therapy in people with cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisVaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisMeasuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical reviewOral anti-pseudomonal antibiotics for cystic fibrosisInhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomesPseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung InfectionsInhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road aheadColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyPseudomonas aeruginosa biofilms in cystic fibrosisDefective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosisA novel virulence strategy for Pseudomonas aeruginosa mediated by an autotransporter with arginine-specific aminopeptidase activityPA3297 Counteracts Antimicrobial Effects of Azithromycin in Pseudomonas aeruginosa.Lung infections associated with cystic fibrosis.Sound waves effectively assist tobramycin in elimination of Pseudomonas aeruginosa biofilms in vitro.Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot studyEvaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.Impact of multidrug-resistant organisms on patients considered for lung transplantation.Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteersComparison of culture and qPCR for the detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients.The population genetics of Pseudomonas aeruginosa isolates from different patient populations exhibits high-level host specificity.Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infectionsRecent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosisVaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis.In vivo fluorescence imaging of bacteriogenic cyanide in the lungs of live mice infected with cystic fibrosis pathogens.Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosisBreakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.
P2860
Q22306318-662DAB1B-C1A7-4FA0-B247-35E15668C6C9Q24187797-3BC8F13F-30B4-47FF-83E3-579EB98E30A4Q24188054-E298D648-7ED2-41B4-8798-E2B83DE68DDAQ24188313-CED8694F-DA9F-444A-9237-582CD92F60A3Q24201445-29D44459-3B4A-4878-93BA-48A8782F8FCAQ24201943-15645B74-ADA9-4A06-B9C2-0BAC18D5BFD4Q24202855-1BB23F12-FAF6-4D90-85EA-7B489D3AB309Q24202879-40D633BC-CB03-4EAE-868E-4B70B81B5513Q24234667-08BFA4D5-B206-48F1-8281-0CE149C0B34AQ24240388-AECAD27F-E689-42A7-9C66-3E5C26DF0D87Q24240779-35B064A9-9CA3-4377-89B7-86D1ED691E4BQ24243916-F53DFCCA-6578-4380-B0CA-95AB5BFDF94CQ24795582-04E926BB-2CD8-4466-A7C4-D21ABD3E7E70Q26471106-A040AC69-F79A-430F-9CCF-F4DB422B2E70Q26764900-0B20C4A0-39B4-4E1B-8158-013B629285C7Q26768034-DE8061A4-5A8E-4685-984B-29BB5A349DFAQ26822988-D2D16E6E-50E4-4D41-9F4E-51C39BCBFC24Q27014993-C25FBCED-679A-4D00-8E65-E94ECD6938A5Q28299966-77580CFD-7F15-4F02-8198-12ADF2719C58Q28479231-DF53601D-3621-40EB-9770-DE2F59FE9699Q28492745-8F9D7FA3-0C5E-447D-A9E9-289494FA997AQ29346778-3351AE60-645C-4AEA-90D5-C5B2A966A64AQ30080000-D964B4EE-D956-4EA2-AA85-626BCB404FFBQ30404353-7A3D9541-4418-4941-BC89-D784EA1CEF16Q30413773-B97B56F5-900E-4BF6-B23C-D21F90C21808Q30442057-29C0ACDA-ADE7-4A9F-AD5C-C42BF651DC1DQ30790275-D08D4576-085E-4E0C-8304-20793075D767Q33474273-696C9523-C2F0-4438-BDF2-11A060973ADDQ33576059-B470DB87-4C9B-4C9F-9508-96E975BFD0CDQ33676387-7A22AF04-9D69-47F3-AD8A-B3CE8ECFA86CQ33702702-44BBC845-AA86-441A-B974-3580189E579CQ33728209-2A82E06A-8334-44C0-B15C-875433229E35Q33786154-5A91AB98-E738-49B4-BA2D-AD9742F0D024Q33862073-F1E85F8A-100B-4D9A-BD59-354E82D510ABQ33909805-0D4A9C01-47BA-4C3C-B2DF-EA714876D100Q33959291-283EEE90-BC25-4F42-B286-839C626CD041Q34041909-2BDB92F3-CEF0-43BB-BF49-1870A36FBA94Q34042263-0A2545A6-DBF2-4B21-8EB9-2F6BB44C0F3CQ34073568-FE48C648-31A7-4F57-A270-C02C3FB9711FQ34243590-3B007F42-C8D4-4892-81DD-E70C1635DFC0
P2860
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@ast
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@en
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@nl
type
label
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@ast
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@en
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@nl
prefLabel
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@ast
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@en
Antibiotic therapy against Pse ...... ibrosis: a European consensus.
@nl
P2093
P1476
Antibiotic therapy against Pse ...... fibrosis: a European consensus
@en
P2093
P304
P356
10.1034/J.1399-3003.2000.16D30.X
P577
2000-10-01T00:00:00Z